(Q40687192)

22 September 2017

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs (English)

1 reference

22 September 2017

1 reference

1 reference

Tipping AJ

1

1 reference

22 September 2017

Mahon FX

2

1 reference

22 September 2017

Zafirides G

3

1 reference

22 September 2017

Lagarde V

4

1 reference

22 September 2017

Goldman JM

5

1 reference

22 September 2017

Melo JV

6

1 reference

22 September 2017

1 December 2002

1 reference

22 September 2017

1 reference

22 September 2017

16

1 reference

22 September 2017

2349-2357

1 reference

22 September 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402775

22 September 2017

0 references

cites work

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Effect of hydroxyurea on ribonucleotide reductase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Cytokine therapeutics: lessons from interferon alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Recombinant Leukocyte A Interferon: Pharmacokinetics, Single-Dose Tolerance, and Biologic Effects in Cancer Patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402775

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402775

1 reference

Dimensions Publication ID

22 September 2017

0 references

1 reference